2023 年 9 月 12 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《嘉和美康关于 2022 年股票期权与限制性股票激励计划首次授予部分第一个行 权期自主行权实施公告》（公告编号：2023-054），根据可交易日及行权手续办 理情况，实际可行权期限为 2023 年 9 月 15 日至 2024 年 7 月 14 日，行权方式为 自主行权。截至 2024 年 3 月 31 日，2022 年股票期权与限制性股票激励计划首 次授予的股票期权和预留授予的股票期权累计行权数量与完成股份过户登记数 量为 164,167 股。 公司于 2023 年 12 月 29 日召开了第四届董事会第十五次会议和第四届监事 会第十三次会议，审议通过了《关于 2022 年股票期权与限制性股票激励计划预 留授予部分第一个归属期归属条件成就的议案》。根据中国证券监督管理委员会、 上海证券交易所、中国证券登记结算有限责任公司上海分公司有关业务规则的规 定，公司于 2024 年 1 月 11 日已完成 2022 年股票期权与限制性股票激励计划预 留授予部分第一个归属期的股份登记工作，并于同日收到中国证券登记结算有限 责 ...

嘉和美康（北京）科技股份有限公司 董事会关于独立董事 2023 年度独立性自查情况的专 项报告 经核查独立董事石向欣、任宏、王韵的任职经历以及签署的相关自查文件， 上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司独立董 事管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》中对独立董事独立性的相关要求。 嘉和美康（北京）科技股份有限公司董事会 2023 年 4 月 26 日 根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等要求，嘉和美康（北京）科技股份有限公司（以下简称"公 司"）董事会就公司在任独立董事石向欣、任宏、王韵的独立性情况进行评估并 出具如下专项意见： ...

嘉和美康（北京）科技股份有限公司 2023 年度独立董事述职报告 作为嘉和美康（北京）科技股份有限公司（以下简称"公司"或"嘉和美康"） 的独立董事，2023年我严格按照《公司法》、《证券法》、《上市公司治理准则》、 《上市公司独立董事管理办法》以及《公司章程》、公司《独立董事工作制度》 的相关要求，在履职过程中做到勤勉尽责，积极参加股东大会、董事会和各专业 委员会会议，就有关事项发表独立意见，充分发挥独立董事的作用，切实维护全 体股东尤其是中小股东的合法权益。现将2023年度履职情况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 石向欣先生，1956年8月出生，中国国籍，无境外永久居留权，北京工业大 学学士，北京大学硕士。1972年5月至1976年12月任北京平谷插队民办教师；1976 年1月至1981年8月任北京汽车塑料件厂电工及助理；1985年9月至1987年11月任 中国人民大学教师；1987年12月至1995年5月任国家轻工业部秘书；1995年5月至 2005年12月任北京华讯集团副总裁；2005年7月至今任北京大洋信通科技有限公 司执行董事、总经理；2003年11月至今任 ...

嘉和美康（北京）科技股份有限公司 审计报告 大华审字[2024]0011004780 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) DaHuaCertifiedPublicAccountants（SpecialGeneralPartnership） ⠨≏ḛ媢ⴉᶌ↢ㅁ漑䅺㪋㕯弛⌉Ḛ漒 ∖ᶫⴁ㱶㲿∹塾◚䊮ᴬ峮 濄濉 ⋶敡 濊 ⋶㡻 濄濅 ⭁濮濄濃濃濃濆濌濰 䐴嫜漡濋濉澻濄濃澼濈濋濆濈濃濃濄濄 ḟ䘞漡濋濉澻濄濃澼濈濋濆濈濃濃濃濉 瀊瀊瀊濁濷濴濻瀈濴激濶瀃濴濁濶瀂瀀 审 计 报 告 བྷॾᇑᆇ>@ਧ 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mcf.gov.cn）"进行查 " హ઼㖾ᓧ˄ेӜ˅、ᢰ㛑ԭᴹ䲀ޜਨ ᇑ䇑ᣕ৺䍒࣑ᣕ㺘 ˄ ᒤ ᴸ ᰕ㠣 ᒤ ᴸ ᰕ→˅ | | ⴞᖅ | 亥⅑ | | --- | --- | --- | | аǃ | ᇑ䇑ᣕ੺ | | | Ҽǃ | ᐢᇑ䍒࣑ᣕ㺘 | | | | ਸᒦ䍴ӗ䍏٪㺘 | | | | ਸᒦ࡙⏖㺘 | | | | ਸᒦ⧠䠁⍱䟿㺘 | | | | ਸᒦ㛑ьᵳ⳺ਈࣘ㺘 | | | | ⇽ޜਨ䍴ӗ䍏٪㺘 | | | | ...

证券代码：688246 证券简称：嘉和美康 公告编号：2024-019 嘉和美康（北京）科技股份有限公司 关于 2024 年度对外担保预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 被担保方：全资子公司北京嘉和美康信息技术有限公司（以下简称"嘉和 信息"）、控股孙公司北京嘉和海森健康科技有限公司（以下简称"嘉和海森"）、 北京生命科学园生物科技研究院有限公司（以下简称"生科研究院"）。 本次担保金额及已实际为其提供的担保余额：嘉和美康（北京）科技股 份有限公司（以下简称"公司"、"嘉和美康"）预计 2024 年度为嘉和信息、嘉 和海森、生科研究院提供担保额度合计不超过人民币 70,000 万元（含）。截至 本公告披露日，公司对外担保余额为 28,506 万元，全部为公司对子公司的担 保。 被担保人是否提供反担保：否 本事项已经公司第四届董事会第十七次会议审议通过，尚需提交 2023 年 年度股东大会进行审议。 一、担保情况概述 为满足公司日常生产经营与业务发展需求，保证其业务顺利开展，结合公司 ...

2024 年 4 月 27 日 证券代码：688246 证券简称：嘉和美康 公告编号：2024-023 嘉和美康（北京）科技股份有限公司 关于变更审计委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召开第四届董事会第十七次会议，审议通过了《关于变更审计委员会委员的议 案》，具体内容如下： 根据中国证券监督管理委员会颁布的《上市公司独立董事管理办法》有关规 定，公司董事会审计委员会委员应当为不在上市公司担任高级管理人员的董事。 为完善公司治理结构，充分发挥董事会专门委员会在上市公司治理中的作用，公 司对第四届董事会审计委员会部分委员进行调整，公司董事、副总经理、财务负 责人任勇先生不再担任审计委员会委员职务。任勇先生辞去审计委员会委员职务 后，仍担任公司董事、副总经理、财务负责人职务。 为保障审计委员会的正常运行，根据《中华人民共和国公司法》《上市公司 独立董事管理办法》以及《公司章程》等相关规定，公司董事会同意选举董事张 ...

嘉和美康（北京）科技股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年年度股东大会 召开日期时间：2024 年 5 月 21 日 14 点 30 分 召开地点：北京市海淀区上地开拓路 7 号一段一层会议室 证券代码：688246 证券简称：嘉和美康 公告编号：2024-022 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 21 日 至 2024 年 5 月 21 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2024年5月21日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 东大会 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2024-024 嘉和美康（北京）科技股份有限公司 关于变更回购公司股份用途的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召开第四届董事会第十七次会议，审议通过了《关于变更回购公司股份用途的 议案》，同意对回购公司股份的用途进行调整，本次回购股份用途由"用于员工 持股计划或股权激励"变更为"用于注销以减少注册资本"。除该项内容修改外， 回购方案中其他内容均不作变更。具体内容如下： 一、原回购方案简介 公司于 2023 年 8 月 22 日召开第四届董事会第十一次会议，审议通过了《关 于以集中竞价交易方式回购股份方案的议案》，同意公司使用超募资金通过集中 竞价交易方式进行股份回购。回购股份将用于员工持股计划或股权激励，回购价 格不超过人民币 39.50 元/股，回购资金总额不低于人民币 3,000 万元且不超过 人民币5,000万元，回购期限为董事会审议通过回购股份方案之日起1 ...

Financial Performance - The net profit attributable to the parent company for 2023 is CNY 42,497,439.19, while the consolidated undistributed profit is CNY -84,417,293.52[5] - The company will not distribute profits for 2023 due to existing undistributed losses and plans to cancel repurchased shares to enhance earnings per share[5] - The company's operating revenue for 2023 was RMB 695,175,319.22, a decrease of 3.04% compared to RMB 716,948,756.64 in 2022[21] - The net profit attributable to shareholders for 2023 was RMB 42,497,439.19, down 37.53% from RMB 68,024,427.15 in the previous year[21] - The basic earnings per share for 2023 was RMB 0.31, a decline of 36.73% from RMB 0.49 in 2022[23] - The total assets at the end of 2023 were RMB 2,646,904,334.03, reflecting a 4.74% increase from RMB 2,527,045,461.81 at the end of 2022[21] - The weighted average return on equity decreased to 2.34% in 2023, down 1.50 percentage points from 3.84% in 2022[23] - The net cash flow from operating activities improved by RMB 116,115,977.11 compared to the previous year, although it remained negative at -143,101,783.01[25] - The gross profit margin for 2023 was 51.76%, an increase of 0.66 percentage points year-on-year[128] - Operating costs decreased by 4.35% to RMB 335.32 million from RMB 350.57 million in the previous year[127] Research and Development - Research and development expenses accounted for 32.72% of operating revenue, an increase of 8.01 percentage points compared to 24.71% in 2022[23] - Research and development investment reached 227.43 million yuan, an increase of 28.38% year-on-year, with 70% of the workforce focused on R&D, totaling 705 employees[36] - The company applied for 40 new invention patents and received 17 invention patent authorizations during the reporting period, with a total of 45 authorized invention patents by the end of the period[37] - The company’s R&D strategy focuses on integrating AI technologies to enhance existing products and develop new models[90] - The total R&D investment increased by 28.38% year-on-year, reaching ¥227,428,325.26, with a significant rise in capitalized R&D investment by 349.36% to ¥82,502,573.28[89] - The company has developed multiple specialized electronic medical record (EMR) products, including those for anesthesia, intensive care, and obstetrics, enhancing diagnostic efficiency and quality[108] Technology and Innovation - The company is investing in AI technology development, including creating its own large model and integrating it with existing specialized models[24] - The company has developed a comprehensive smart medical product system driven by artificial intelligence, covering clinical diagnosis, research support, medical management, and patient services[57] - The integration of new technologies such as AI, big data, and cloud computing is driving the evolution of medical software systems towards smarter and more integrated solutions[80] - The company has developed key technologies in medical natural language processing, achieving an accuracy rate of over 95% in clinical decision-making models[24] - The intelligent clinical decision-making engine achieved a diagnostic accuracy rate of over 98% in practical clinical applications[26] Market Position and Strategy - The company has maintained the number one position in the electronic medical record (EMR) market in China for nine consecutive years from 2014 to 2022, according to IDC data[75] - The company has over 1,600 hospital clients nationwide, including more than 600 top-tier hospitals, representing over 25% of all top-tier hospitals in China[75] - The company holds a leading position in the electronic medical record segment with a market share of 17.7%, ahead of competitors such as Weining Health (14.1%) and Haitai Medical (13.1%)[117] - In the medical big data solutions segment, the company also ranks first with an 8.8% market share, surpassing Shenzhou Medical (7.8%) and Weining Health (7.6%)[117] - The company aims to become a leading enterprise in the domestic medical information industry, focusing on clinical information construction and following the development path of "informationization - digitalization - intelligence"[158] Governance and Compliance - The company has confirmed that all board members attended the board meeting, ensuring governance compliance[8] - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7] - The company has not experienced any violations in decision-making procedures regarding external guarantees[8] - The company has established a remuneration committee to oversee the compensation plans for directors and senior management[181] - The company has not faced any penalties from securities regulatory agencies in the past three years[184] Employee and Management - The total number of employees in the parent company is 45, while the main subsidiaries employ 2,005, resulting in a total of 2,050 employees[195] - Among the total employees, there are 1,677 technical personnel, 224 sales personnel, and 123 administrative personnel[195] - The company has a structured approach to remuneration, considering economic conditions and industry standards to motivate management while protecting shareholder interests[181] - The company has implemented various equity incentive plans to motivate and retain key personnel[170] - The company has a total of 86 employees with master's degrees or higher, and 1,259 employees with bachelor's degrees[195] Future Outlook - The company provided a forward guidance of 10% revenue growth for the next quarter, projecting $550 million in revenue[174] - The company plans to implement new marketing strategies aimed at increasing brand awareness by 40% in the next year[174] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[178] - The company plans to further enhance brand awareness and overall strength through competitive compensation systems and equity incentives to retain and motivate professional talent[162]

Financial Performance - The company's operating revenue for Q1 2024 was ¥122,559,648.25, representing a year-on-year increase of 14%[5] - The net profit attributable to shareholders was -¥11,850,583.19, and the net profit after deducting non-recurring gains and losses was -¥13,035,632.66, with no applicable percentage change[5] - The net cash flow from operating activities was -¥96,963,002.49, indicating a negative cash flow situation[6] - Total operating revenue for Q1 2024 was CNY 122,559,648.25, an increase of 14.0% compared to CNY 107,504,828.76 in Q1 2023[19] - Net loss for Q1 2024 was CNY 16,002,665.06, an improvement from a net loss of CNY 31,354,681.56 in Q1 2023, indicating a 48.9% reduction in losses[22] - The company reported a total comprehensive loss of CNY 16,002,665.06 for Q1 2024, compared to a total comprehensive loss of CNY 31,354,681.56 in Q1 2023[22] Cash Flow - The company's cash and cash equivalents decreased to RMB 534,817,691.78 from RMB 612,478,452.28, representing a decline of about 12.7%[16] - Cash flow from operating activities increased to CNY 103,325,688.82 in Q1 2024 from CNY 99,076,074.81 in Q1 2023, reflecting a growth of 4.5%[24] - Net cash flow from operating activities was -$96,963,002.49, an improvement from -$147,248,515.51 in the previous year, indicating a 34% reduction in cash outflow[25] - Total cash inflow from financing activities was $106,381,513.11, significantly higher than $18,000,000.00 in the same quarter last year[26] - Cash outflow for financing activities totaled $30,496,269.17, compared to $97,378,156.05 in the previous year, reflecting a 69% decrease[26] - The net cash flow from financing activities was $75,885,243.94, a turnaround from -$79,378,156.05 in the previous year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,692,097,781.16, reflecting a 1.71% increase compared to the end of the previous year[6] - The company's short-term borrowings increased to RMB 259,720,809.73 from RMB 179,667,517.16, reflecting a significant rise of approximately 44.5%[17] - Total liabilities increased to CNY 872,995,330.30 in Q1 2024 from CNY 804,941,532.26 in Q1 2023, marking an increase of 8.5%[19] - The total current liabilities amounted to RMB 1,000,000,000, which is a critical figure for assessing liquidity[17] Shareholder Information - The company reported a total of 5,613 ordinary shareholders at the end of the reporting period[12] - The top shareholder, Xia Jun, holds 24,750,839 shares, representing 17.8% of the total shares[12] Research and Development - Research and development expenses totaled ¥59,773,809.35, accounting for 48.77% of operating revenue, a decrease of 1.23 percentage points year-on-year[6] - Research and development expenses decreased to CNY 32,077,752.04 in Q1 2024 from CNY 44,689,485.21 in Q1 2023, a decline of 28.3%[19] - The company has invested RMB 128,558,810.44 in development expenditures, up from RMB 100,862,753.13, indicating a growth of approximately 27.5%[17] Government Subsidies - The company received government subsidies amounting to ¥1,803,182.66, which are closely related to its normal business operations[7]